胸部放疗联合同期卡铂-紫杉醇或顺铂-依托泊苷治疗III期非小细胞肺癌的比较:一项系统综述
该系统综述纳入31项顺铂-依托泊苷研究共3090例和48项卡铂-紫杉醇研究共3728例III期不可切除非小细胞肺癌患者,比较两种同步放化疗方案的疗效与毒性。结果显示两组在缓解率、无进展生存、总生存及3年生存率上无显著差异,但顺铂-依托泊苷组3-4级血液学毒性更高,毒性特征倾向于卡铂-紫杉醇方案。
要点
- 顺铂-依托泊苷与卡铂-紫杉醇同步胸部放疗的疗效相当,缓解率、生存均无显著差异
- 顺铂-依托泊苷组3-4级中性粒细胞减少和恶心呕吐发生率显著高于卡铂-紫杉醇组
- 两组3-4级肺炎和食管炎发生率相似,毒性特征倾向于卡铂-紫杉醇方案
核心结论
- 对于III期不可切除非小细胞肺癌患者,顺铂-依托泊苷与卡铂-紫杉醇联合同期根治性放疗的疗效相当,毒性特征倾向于卡铂-紫杉醇方案。
研究设计与样本
- 系统综述,检索MEDLINE、EMBASE和Cochrane图书馆及会议摘要,纳入接受胸部放疗联合卡铂-紫杉醇或顺铂-依托泊苷的III期患者研究,排除1期试验、入组少于10例及包含手术切除的研究。
- 顺铂-依托泊苷组共31项研究3090例(中位年龄61岁,65%男性,40%鳞癌,中位放疗剂量63.0 Gy),卡铂-紫杉醇组共48项研究3728例(中位年龄63岁,65%男性,40%鳞癌,中位放疗剂量64.6 Gy)。
主要发现
- 顺铂-依托泊苷组与卡铂-紫杉醇组缓解率分别为58%与56%(P=0.26),无显著差异。
- 顺铂-依托泊苷组与卡铂-紫杉醇组中位无进展生存分别为12个月与9.3个月(P=0.20),中位总生存分别为19.6个月与18.4个月(P=0.40),3年生存率分别为31%与25%(P=0.50),均无显著差异。
- 顺铂-依托泊苷组3-4级中性粒细胞减少发生率为54%,卡铂-紫杉醇组为23%(P<0.001);3/4级恶心呕吐发生率分别为20%与11%(P=0.03)。
- 顺铂-依托泊苷组与卡铂-紫杉醇组3-4级肺炎发生率分别为12%与9%(P=0.12),3-4级食管炎发生率分别为23%与21%(P=0.27),均相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. There are no prospective comparisons of these 2 regimens in this setting. OBJECTIVE: To conduct a systematic review of published trials to compare outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in patients with non-small-cell lung cancer receiving thoracic radiation. EVIDENCE REVIEW: Studies that enrolled patients with stage III disease receiving radiotherapy (RT) with carboplatin-paclitaxel or cisplatin-etoposide were identified using electronic databases (MEDLINE, EMBASE, and Cochrane library) and meeting abstracts. Trials were excluded if they were phase 1, enrolled less than 10 patients, or included surgical resection. A systematic analysis of extracted data was performed with software using random and fixed effect models. Clinical outcomes were compared using point estimates for weighted values of median overall survival, progression-free survival, response rate, and toxic effects. A 2-tailed t test with a significance level of .05 was used for all comparisons. FINDINGS: Overall, 3090 patients were included from 31 studies in the cisplatin-etoposide groups (median age, 61 years; 65% male; 40% squamous histology; median radiation dose, 63.0 Gy), and 3728 patients from 48 studies in carboplatin-paclitaxel groups (median age, 63 years; 65% male; 40% squamous histology; median radiation dose, 64.6 Gy). There was no significant difference in response rates between cisplatin-etoposide and carboplatin-paclitaxel (58% vs 56%; P = .26), respectively. For cisplatin-etoposide vs carboplatin-paclitaxel, there was no significant difference in median progression free survival (12 months vs 9.3 months; P = .20), overall survival (19.6 months vs 18.4 months; P = .40), or 3-year survival rate (31% vs 25%; P = .50). Cisplatin-etoposide was associated with higher grade 3 to 4 hematological toxic effects compared with carboplatin-paclitaxel (eg, neutropenia [54% vs 23%; P < .001] and grade 3/4 nausea/vomiting [20% vs 11%; P = .03]), while rates of grade 3 to 4 pneumonitis (12% vs 9%; P = .12) and esophagitis (23% vs 21%; P = .27) were similar. CONCLUSIONS AND RELEVANCE: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. The toxic effect profiles favored the carboplatin-paclitaxel regimen.
引用
- Steuer CE, Behera M, Ernani V, et al. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. JAMA Oncol. 2017. PMID: 27978552. doi:10.1001/jamaoncol.2016.4280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。